Select a medication above to begin.
Riabni (rituximab-arrx)
rituximab
Black Box Warnings .
Infusion Rxns
serious, incl. fatal infusion rxns can occur; deaths reported w/in 24h of infusion; approx. 80% fatal infusion rxns occur w/ 1st infusion; monitor pts closely; D/C tx and treat severe infusion rxns
Severe Mucocutaneous Rxns
can occur, incl. fatal rxns
HBV Reactivation
can occur, incl. cases resulting in fulminant hepatitis, hepatic failure, and death; screen all pts for HBV infection before initial tx; monitor for s/sx HBV reactivation during tx and after D/C; D/C rituximab and concomitant drugs if HBV reactivation occurs
Progressive Multifocal Leukoencephalopathy
can occur, incl. fatal PML
Adult Dosing .
Dosage forms: INJ
Special Note
- [drug name clarification]
- Info: nonproprietary name = rituximab-arrx
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses, premeds, and dosing incl. toxicity-related dose adjustments
CD20-positive B-Cell non-Hodgkin lymphoma, relapsed or refractory
- [monotherapy]
- Dose: 375 mg/m^2/dose IV qwk x4wk or x8wk; Info: for pts w/ low-grade or follicular dz; may give additional 4wk tx in pts who progress after initial tx; give HBV prophylaxis before tx start, during tx, and for up to 12mo after D/C in anti-HBc positive pts
- [ibritumomab tiuxetan combo tx]
- Dose: 250 mg/m^2/dose IV x1 on day 1, then on days 7, 8, or 9 of regimen; Info: for pts w/ low-grade or follicular dz; give HBV prophylaxis before tx start, during tx, and for up to 12mo after D/C in anti-HBc positive pts
CD20-positive B-Cell non-Hodgkin lymphoma, previously untreated
- [follicular type, chemo combo tx]
- Dose: 375 mg/m^2/dose IV x1 on day 1 of each cycle; Info: give up to 8 cycles; if complete or partial response achieved, may give maint. monotherapy 375 mg/m^2/dose IV x1 on day 1 of 56-day cycle x12 cycles starting 56 days after completion of 1st-line combo chemo; give HBV prophylaxis before tx start, during tx, and for up to 12mo after D/C in anti-HBc positive pts
- [follicular type, ibritumomab tiuxetan combo tx]
- Dose: 250 mg/m^2/dose IV x1 on day 1, then on days 7, 8, or 9 of regimen; Info: for pts w/ complete or partial response after completion of 1st-line combo chemo; give HBV prophylaxis before tx start, during tx, and for up to 12mo after D/C in anti-HBc positive pts
- [diffuse large B-cell type, chemo combo tx]
- Dose: 375 mg/m^2/dose IV x1 on day 1 of each cycle; Info: give up to 8 cycles; give HBV prophylaxis before tx start, during tx, and for up to 12mo after D/C in anti-HBc positive pts
CD20-positive B-Cell non-Hodgkin lymphoma, non-progressing
- [375 mg/m^2/dose IV x1 on days 1, 8, 15, 22 of 6-mo cycle]
- Start: after completion of 1st-line combo chemo; Info: for pts w/ low-grade dz; give up to 16 doses (4 cycles); give HBV prophylaxis before tx start, during tx, and for up to 12mo after D/C in anti-HBc positive pts
CD20-positive CLL/SLL
- [500 mg/m^2/dose IV x1 on day 1 of 28-day cycle, starting cycle 2]
- Start: 375 mg/m^2/dose IV x1 on the day before cycle 1; Info: give x6 cycles; part of multi-drug chemo regimen; give HSV and PCP prophylaxis during tx and up to 12mo after D/C; give HBV prophylaxis before tx start, during tx, and for up to 12mo after D/C in anti-HBc positive pts
rheumatoid arthritis, moderate-severe
- [1000 mg IV q2wk x2 doses]
- Info: for pts w/ inadequate response to TNF antagonist; may repeat course q16-24wk; use w/ methotrexate; give HBV prophylaxis before tx start, during tx, and for at least 12mo after D/C in anti-HBc positive pts
granulomatosis w/ polyangiitis (GPA)
- [induction tx]
- Dose: 375 mg/m^2/dose IV qwk x4wk; Info: use w/ glucocorticoids; give PCP prophylaxis during tx and for at least 6mo after D/C; give HBV prophylaxis before tx start, during tx, and for at least 12mo after D/C in anti-HBc positive pts
- [subsequent tx]
- Dose: 500 mg IV q2wk x2 doses, then 500 mg IV q6mo; Start: 16-24wk after last induction tx w/ rituximab, or w/in 4wk of dz control achieved w/ other standard of care immunosuppressants; Info: give PCP prophylaxis during tx and for at least 6mo after D/C; give HBV prophylaxis before tx start, during tx, and for at least 12mo after D/C in anti-HBc positive pts
microscopic polyangiitis (MPA)
- [induction tx]
- Dose: 375 mg/m^2/dose IV qwk x4wk; Info: use w/ glucocorticoids; give PCP prophylaxis during tx and for at least 6mo after D/C; give HBV prophylaxis before tx start, during tx, and for at least 12mo after D/C in anti-HBc positive pts
- [subsequent tx]
- Dose: 500 mg IV q2wk x2 doses, then 500 mg IV q6mo; Start: 16-24wk after last induction tx w/ rituximab, or w/in 4wk of dz control achieved w/ other standard of care immunosuppressants; Info: give PCP prophylaxis during tx and for at least 6mo after D/C; give HBV prophylaxis before tx start, during tx, and for at least 12mo after D/C in anti-HBc positive pts
pemphigus vulgaris, moderate-severe
- [500 mg IV q6mo]
- Start: 1000 mg IV q2wk x2 doses, then starting at mo 12, give 500 mg IV q6mo; Info: use w/ glucocorticoids; may give additional 1000 mg IV x1 if relapse; maintenance and relapse doses should be dosed at least 16wk apart; consider PCP prophylaxis; give HBV prophylaxis before tx start, during tx, and for at least 12mo after D/C in anti-HBc positive pts
myasthenia gravis (off-label)
- [375 mg/m^2/dose IV qwk x4wk]
- Alt: 1000 mg IV q2wk x2 doses; Info: may repeat course or give maintenance doses q1-6mo
renal dosing
- [see below]
- renal impairment: no adjustment
- HD: no adjustment; no supplement; PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
- Dosage forms: INJ
Special Note
- [drug name clarification]
- Info: nonproprietary name = rituximab-arrx
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses, premeds, and dosing incl. toxicity-related dose adjustments
CD20-positive B-Cell non-Hodgkin lymphoma (off-label)
- [previously untreated, 6 mo and older]
- Dose: 375 mg/m^2/dose IV on days -2 and 1 during induction tx x2 cycles, then 375 mg/m^2/dose IV on day 1 during consolidation tx x2 cycles (total of 6 doses); Info: for pts w/ advanced stage, diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia; part of multi-drug chemo regimen (Lymphome Malin B); give HBV prophylaxis before tx start, during tx, and for up to 12mo after D/C in anti-HBc positive pts
- [retreatment, 2 yo and older]
- Dose: 375 mg/m^2/dose IV qwk x4wk, may repeat q6mo x2y; Info: give HBV prophylaxis before tx start, during tx, and for up to 12mo after D/C in anti-HBc positive pts
- [relapsed or refractory, 2 yo and older]
- Dose: 375 mg/m^2/dose IV x1 on day 1 of each cycle; Start: 375 mg/m^2/dose IV x1, give 48h before cycle 1; Info: give x3 cycles (4 doses); part of multi-drug chemo regimen; give HBV prophylaxis before tx start, during tx, and for up to 12mo after D/C in anti-HBc positive pts
- [ibritumomab tiuxetan combo tx, 2 yo and older]
- Dose: 250 mg/m^2/dose IV x1 on day 1, then on days 7, 8, or 9 of regimen; Info: for pts w/ relapsed or refractory low-grade, follicular or transformed dz; give HBV prophylaxis before tx start, during tx, and for up to 12mo after D/C in anti-HBc positive pts
B-cell precursor ALL, relapsed or refractory (off-label)
- [2 yo and older]
- Dose: 375 mg/m^2/dose IV on days 1 and 3 of cycles 1 and 2, and on day 3 only of cycle 3; Info: give up to 3 cycles; part of multi-drug chemo regimen
granulomatosis w/ polyangiitis (GPA) (off-label)
- [induction tx, 2 yo and older]
- Dose: 375 mg/m^2/dose IV qwk x4wk; Info: use w/ glucocorticoids; give PCP prophylaxis during tx and for at least 6mo after D/C; give HBV prophylaxis before tx start, during tx, and for at least 12mo after D/C in anti-HBc positive pts
- [subsequent tx, 2 yo and older]
- Dose: 250 mg IV q2wk x2 doses, then 250 mg IV q6mo; Start: 16-24wk after last induction tx w/ rituximab, or w/in 4wk of dz control achieved w/ other standard of care immunosuppressants; Info: give PCP prophylaxis during tx and for at least 6mo after D/C; give HBV prophylaxis before tx start, during tx, and for at least 12mo after D/C in anti-HBc positive pts
microscopic polyangiitis (MPA) (off-label)
- [induction tx, 2 yo and older]
- Dose: 375 mg/m^2/dose IV qwk x4wk; Info: use w/ glucocorticoids; give PCP prophylaxis during tx and for at least 6mo after D/C; give HBV prophylaxis before tx start, during tx, and for at least 12mo after D/C in anti-HBc positive pts
- [subsequent tx, 2 yo and older]
- Dose: 250 mg IV q2wk x2 doses, then 250 mg IV q6mo; Start: 16-24wk after last induction tx w/ rituximab, or w/in 4wk of dz control achieved w/ other standard of care immunosuppressants; Info: give PCP prophylaxis during tx and for at least 6mo after D/C; give HBV prophylaxis before tx start, during tx, and for at least 12mo after D/C in anti-HBc positive pts
pemphigus vulgaris, moderate-severe (off-label)
- [9 yo and older]
- Dose: 500 mg IV q2wk x2 doses; Alt: 375 mg/m^2/dose IV q2wk x2 doses; Info: consider PCP prophylaxis; give HBV prophylaxis before tx start, during tx, and for at least 12mo after D/C in anti-HBc positive pts
autoimmune hemolytic anemia, refractory (off-label)
- [4 mo and older]
- Dose: 375 mg/m^2/dose IV qwk x2-4wk
chronic ITP (off-label)
- [3 mo and older]
- Dose: 375 mg/m^2/dose IV qwk x4wk
post-transplant lymphoproliferative disorder (off-label)
- [11 mo and older]
- Dose: 375 mg/m^2/dose IV qwk x3-4wk
SLE, refractory (off-label)
- [8 yo and older]
- Dose: 375 mg/m^2/dose IV qwk x2-4wk; Alt: 750 mg/m^2/dose IV x1 on day 1 and 15 of regimen; Max: 1000 mg/dose
nephrotic syndrome, refractory (off-label)
- [11 mo and older]
- Dose: 375 mg/m^2/dose IV qwk x1-4wk; Max: 500 mg/dose
renal dosing
- [not defined]
- renal impairment: consider adult renal dosing for guidance
- HD/PD: consider adult renal dosing for guidance
hepatic dosing
- [not defined]
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- hypersensitivity to murine protein
- infection, active severe
- avoid: breastfeeding during tx and x6mo after D/C
- caution: pts of childbearing potential
- caution: elderly pts
- caution: infection, latent
- caution: infection, chronic
- caution: HBV carriers
- caution: cardiovascular dz
- caution: cardiovascular dz hx
- caution: angina
- caution: angina hx
- caution: arrhythmia hx
- caution: pulmonary dz
- caution: tumor burden, high
Drug Interactions .
Overview
rituximab
CD20 antigen inhibitor
- hyperuricemic effects
- immunosuppressive effects
- immunosuppressive oncologic agent
- myelosuppressive effects
- myelosuppressive oncologic agent
- nephrotoxicity
Contraindicated
- adenovirus vaccine, live
- BCG live intravesical
- chikungunya vaccine, live
- cholera vaccine, live
- cidofovir
- dengue vaccine, live
- influenza nasal vaccine, live
- measles/mumps/rubella vaccine, live
- rotavirus vaccine, live
- smallpox vaccine, live
- talimogene laherparepvec
- typhoid vaccine, live
- varicella vaccine, live
- yellow fever vaccine, live
Avoid/Use Alternative
- abatacept
- abrocitinib
- adalimumab
- aldesleukin
- amikacin
- amikacin inhaled
- anifrolumab
- belimumab
- bumetanide
- certolizumab pegol
- chloramphenicol
- cisplatin
- cladribine oral
- clofarabine
- deferiprone
- deuruxolitinib
- dexrazoxane
- efgartigimod alfa
- etrasimod
- fexinidazole
- foscarnet
- ganciclovir
- gentamicin
- golimumab
- infliximab
- mannitol
- methotrexate
- natalizumab
- nipocalimab
- oxaliplatin
- palifermin
- penicillamine
- pentamidine
- pimecrolimus topical
- polymyxin B
- primaquine
- rabies vaccine
- radium Ra 223 dichloride
- ritlecitinib
- ropeginterferon alfa-2b
- rozanolixizumab
- ruxolitinib topical
- sarilumab
- streptomycin
- streptozocin
- tenofovir disoproxil
- tobramycin
- tobramycin inhaled
- tocilizumab
- tofacitinib
- upadacitinib
- valganciclovir
Monitor/Modify Tx
- abemaciclib
- acalabrutinib
- acyclovir
- adefovir dipivoxil
- ado-trastuzumab emtansine
- afamitresgene autoleucel
- albendazole
- alectinib
- alemtuzumab
- aliskiren
- allopurinol
- amiloride
- amphotericin
- anthrax immune globulin
- anthrax vaccine
- anti-thymocyte globulin
- arsenic trioxide
- asciminib
- asenapine
- aspirin
- atidarsagene autotemcel
- auranofin
- axicabtagene ciloleucel
- axitinib
- azacitidine
- azathioprine
- azilsartan medoxomil
- balsalazide
- baricitinib
- belantamab mafodotin
- belinostat
- benazepril
- bendamustine
- benznidazole
- betibeglogene autotemcel
- bevacizumab
- bexarotene
- bleomycin
- blinatumomab
- bortezomib
- bosutinib
- botulism immune globulin
- brentuximab vedotin
- brexucabtagene autoleucel
- busulfan
- cabazitaxel
- cabozantinib
- candesartan cilexetil
- capecitabine
- captopril
- carboplatin
- carfilzomib
- carmustine
- celecoxib
- chikungunya vaccine
- chlorambucil
- chlorothiazide
- chlorthalidone
- ciltacabtagene autoleucel
- cladribine injection
- clindamycin
- clozapine
- colchicine
- colistimethate
- copanlisib
- COVID-19 vaccine
- creatine
- crizotinib
- cyclophosphamide
- cyclosporine
- cytarabine
- cytomegalovirus immune globulin
- dacarbazine
- dactinomycin
- dapsone
- daratumumab
- dasatinib
- daunorubicin
- decitabine
- deferasirox
- deferoxamine
- diclofenac
- diclofenac topical
- diflunisal
- dinutuximab
- diphtheria/tetanus vaccine
- diphtheria/tetanus/pertussis vaccine
- docetaxel
- dostarlimab
- doxorubicin
- duvelisib
- ebola vaccine, live
- efbemalenograstim alfa
- eflapegrastim (G-CSF)
- eflornithine
- elivaldogene autotemcel
- elranatamab
- enalapril
- enalaprilat
- enfortumab vedotin
- entrectinib
- epcoritamab
- epirubicin
- eribulin
- ethacrynic acid
- etodolac
- etoposide
- everolimus
- exagamglogene autotemcel
- fam-trastuzumab deruxtecan
- febuxostat
- fedratinib
- fenoprofen
- filgrastim (G-CSF)
- floxuridine
- flucytosine
- fludarabine
- fluorouracil
- fluphenazine
- flurbiprofen
- fosinopril
- fostamatinib
- furosemide
- gemcitabine
- gemtuzumab ozogamicin
- givinostat
- glasdegib
- glofitamab
- Haemophilus b vaccine
- hepatitis A vaccine
- hepatitis B vaccine
- human papillomavirus vaccine
- hydrochlorothiazide
- hydroxychloroquine
- hydroxyurea
- ibritumomab tiuxetan
- ibrutinib
- ibuprofen
- ibuprofen lysine
- idarubicin
- idecabtagene vicleucel
- idelalisib
- ifosfamide
- iloperidone
- imatinib
- imetelstat
- immune globulin
- indapamide
- indomethacin
- influenza H5N1 vaccine
- influenza vaccine
- inotuzumab ozogamicin
- interferon beta 1a
- interferon beta 1b
- interferon gamma 1b
- iohexol
- iomeprol
- iopamidol
- irbesartan
- irinotecan
- isatuximab
- ivosidenib
- ixabepilone
- Japanese encephalitis vaccine
- ketoprofen
- ketorolac
- leflunomide
- lenalidomide
- lenvatinib
- lifileucel
- linezolid
- linvoseltamab
- lisinopril
- lisocabtagene maraleucel
- lithium
- lomustine
- lonafarnib
- loncastuximab tesirine
- losartan
- lovotibeglogene autotemcel
- lumateperone
- lurbinectedin
- lutetium Lu 177 dotatate
- lutetium Lu 177 vipivotide tetraxetan
- lymphocyte immune globulin, anti-thymocyte globulin
- magnesium citrate
- magnesium salicylate
- meclofenamate
- mefenamic acid
- meloxicam
- melphalan
- meningococcal vaccine
- mercaptopurine
- mesalamine
- mesalamine rectal
- metolazone
- midostaurin
- mitomycin
- mitotane
- mitoxantrone
- moexipril
- mogamulizumab
- momelotinib
- mosunetuzumab
- mycophenolate mofetil
- mycophenolic acid
- nabumetone
- naproxen
- nelarabine
- neomycin
- nilotinib
- niraparib
- nusinersen
- obecabtagene autoleucel
- obinutuzumab
- ofatumumab
- olaparib
- olmesartan medoxomil
- olsalazine
- osimertinib
- oxaprozin
- paclitaxel
- pacritinib
- palbociclib
- pamidronate
- panobinostat
- paromomycin
- pazopanib
- pegfilgrastim (G-CSF)
- peginterferon alfa 2a
- peginterferon beta 1a
- pegloticase
- pemetrexed
- pentostatin
- perindopril
- piroxicam
- pirtobrutinib
- plazomicin
- pneumococcal vaccine
- polatuzumab vedotin
- poliovirus vaccine
- polyethylene glycol
- polyethylene glycol/electrolytes
- pomalidomide
- ponatinib
- pralatrexate
- probenecid
- procarbazine
- proguanil
- pyrimethamine
- quinapril
- quizartinib
- ramipril
- ramucirumab
- rasburicase
- respiratory syncytial virus vaccine
- Rho(D) immune globulin
- ribavirin
- ribociclib
- rifabutin
- romidepsin
- rucaparib
- ruxolitinib
- sacituzumab govitecan
- salsalate
- sargramostim (GM-CSF)
- satralizumab
- selinexor
- sipuleucel-T
- sirolimus
- sirolimus albumin-bound
- sitagliptin
- smallpox/mpox vaccine, live
- sparsentan
- spironolactone
- stiripentol
- succimer
- sulfasalazine
- sulfate bowel prep
- sulindac
- sunitinib
- tacrolimus
- tafasitamab
- tagraxofusp
- talazoparib
- talquetamab
- tarlatamab
- tazemetostat
- teclistamab
- telavancin
- telmisartan
- temozolomide
- temsirolimus
- tenofovir alafenamide
- teplizumab
- teriflunomide
- thalidomide
- thioguanine
- thiotepa
- tick-borne encephalitis vaccine
- tiopronin
- tisagenlecleucel
- tivozanib
- tolmetin
- topotecan
- torsemide
- trabectedin
- trandolapril
- trastuzumab
- treosulfan
- triamterene
- trifluridine
- trimethoprim
- typhoid vaccine
- vaccinia immune globulin
- valacyclovir
- valproic acid
- valsartan
- vancomycin
- venetoclax
- vinblastine
- vincristine
- vinorelbine
- voclosporin
- willow bark
- zanubrutinib
- zidovudine
- ziv-aflibercept
- zoledronic acid
- zonisamide
- zoster vaccine, recombinant
Caution Advised
- anakinra
- avacopan
- basiliximab
- beclomethasone inhaled
- beclomethasone nasal
- belatacept
- betamethasone
- bimekizumab
- brodalumab
- budesonide
- budesonide inhaled
- budesonide nasal
- budesonide rectal
- canakinumab
- clobetasol ophthalmic
- corticotropin
- cortisone
- crovalimab
- danicopan
- deflazacort
- delgocitinib topical
- deucravacitinib
- dexamethasone
- dexamethasone ophthalmic
- difluprednate ophthalmic
- dimethyl fumarate
- diroximel fumarate
- dupilumab
- eculizumab
- elotuzumab
- emapalumab
- etanercept
- fingolimod
- fludrocortisone
- flunisolide nasal
- fluocinolone intravitreal
- fluorometholone ophthalmic
- fluticasone furoate
- fluticasone propionate
- fruquintinib
- guselkumab
- hydrocortisone
- hydrocortisone ophthalmic
- inebilizumab
- iptacopan
- ixekizumab
- lebrikizumab
- loteprednol ophthalmic
- methylprednisolone
- mirikizumab
- mometasone implant
- mometasone inhaled
- mometasone nasal
- monomethyl fumarate
- nadofaragene firadenovec intravesical
- ocrelizumab
- ozanimod
- pegcetacoplan
- ponesimod
- pozelimab
- prednisolone
- prednisolone ophthalmic
- prednisone
- ravulizumab
- regorafenib
- rilonacept
- risankizumab
- secukinumab
- siltuximab
- siponimod
- spesolimab
- sutimlimab
- tezepelumab
- tildrakizumab
- tralokinumab
- triamcinolone
- tuberculin purified protein derivative
- ublituximab
- ustekinumab
- vamorolone
- vedolizumab
- vilobelimab
- zilucoplan
Adverse Reactions .
Serious Reactions
- infusion rxn, severe
- tumor lysis syndrome
- hypersensitivity rxn, severe
- anaphylaxis
- mucocutaneous rxn, severe
- Stevens-Johnson syndrome
- toxic epidermal necrolysis
- pyoderma gangrenosum
- lymphopenia
- hypogammaglobulinemia, incl. prolonged
- neutropenia, incl. prolonged
- pancytopenia, incl. prolonged
- infection, serious
- sepsis
- PML
- HBV reactivation
- hepatitis, fulminant
- hepatic failure
- pulmonary toxicity
- cardiotoxicity
- ventricular fibrillation
- nephrotoxicity
- GI obstruction
- GI perforation
- posterior reversible encephalopathy syndrome
Common Reactions
- fever
- lymphopenia
- febrile neutropenia
- nausea
- rigors
- stomatitis
- asthenia
- infection
- headache
- arthralgia
- HTN
- rash
- abdominal pain
- leukopenia
- cough
- rhinitis
- night sweats
- diarrhea
- pruritus
- neutropenia
- URI
- anemia
- peripheral edema
- ALT or AST incr.
- pain
- thrombocytopenia
- dizziness
- urticaria
- angioedema
- enteritis
- infusion rxn
- hypotension
- myalgia
- vomiting
- dyspnea
- hyperglycemia
- sepsis
- anxiety
- bronchospasm
- hypokalemia
Safety/Monitoring .
Monitoring Parameters
Non-Hodgkin Lymphoma or CLL/SLL: HBV screening, pregnancy test at baseline; CBC w/ diff prior to each cycle if monotherapy or q1-4wk if combo tx; BUN/Cr; s/sx infusion rxn esp. during 1st infusion; ECG during infusion and immediate post-infusion if cardiac conditions or hx incl. arrhythmias and angina; HBV DNA at baseline, qmo during tx, then q3mo x18-24mo after D/C if current or prior HBV infection; s/sx hepatitis or HBV reactivation during tx and x18-24mo after D/C if current or prior HBV infection
RA or GPA or MPA or PV: HBV screening, pregnancy test at baseline; CBC w/ diff at baseline, then q2-4mo; BUN/Cr; s/sx infusion rxn esp. during 1st infusion; ECG during infusion and immediate post-infusion if cardiac conditions or hx incl. arrhythmias and angina; ALT, HBV DNA at baseline if current or prior HBV infection; ALT, HBsAg, HBV DNA q3mo during tx and x18-24mo after D/C if current or prior HBV infection; s/sx hepatitis or HBV reactivation during tx and x18-24mo after D/C if current or prior HBV infection
Look/Sound-Alike Drug Names
riTUXimab confused with: inFLIXimab
Pregnancy/Lactation .
Pregnancy
Clinical Summary
weigh risk/benefit during pregnancy; no known risk of teratogenicity, though risk of transient B-cell depletion based on limited human data and on animal data
Individuals of Reproductive Potential
obtain pregnancy test before tx start; avoid pregnancy by using effective contraception during tx and x12mo after D/C in pts of childbearing potential
Lactation
Clinical Summary
avoid breastfeeding during tx and x6mo after D/C; inadequate human data available to assess risk of infant harm; no human data available to assess effects on milk production
Pharmacology .
Metabolism: other; CYP450: unknown
Excretion: other; Half-life: 18-32 days
Subclass: DMARDs, B-cell Depletion Agents ; Immunotherapy, CD20 Inhibitors ; Immunotherapy, Post-Transplant Lymphoproliferative Disease ; Myasthenia Gravis
Mechanism of Action
binds to B-lymphocyte CD20 surface antigens, inducing cell lysis of CD20-expressing cells via antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC)
Formulary .
No Formulary Selected
Manufacturer/Pricing .
Manufacturer: Amgen, Inc.
DEA/FDA: Rx
Approximate Retail Price
from http://www.goodrx.com/riabni
intravenous solution:
- 100 mg/10 mL (1 vial, 10 mL): $741.00
- 500 mg/50 mL (1 vial, 10 mL): $741.00
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.